baseclick working towards mRNA therapeutic development utilizing the Nobel Prize awarded “Click Chemistry” bioconjugation technology
Computer-generated image
baseclick has started its own COVID-19 mRNA program utilizing its mRNA modification technology to target sugar modified mRNA specifically to immune cells to raise an immune response against the N-protein of SARS-CoV2, obtaining a positive evaluationfrom the Paul Ehrlich Institute.
Dr. Frischmuth, CEO and inventor of the Click Chemistry mRNA modification technology, expressed his satisfaction for the progress made and his hope “to accelerate the development of mRNA as a new therapeutics class.”
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.